Why Is INSULET CORP (PODD) Stock Down Today?

PODD stock fell 20.12% to $133.26 in a session marked by multiple analyst downgrades and a revised outlook from the company. The decline followed a series of analyst actions targeting Insulet’s growth trajectory, particularly in the competitive insulin pump market and concerns over type 2 diabetes retention. Despite beating second-quarter 2026 earnings estimates, the company cut its full-year revenue guidance, contributing to the sharp sell-off.

What Happened

Truist, Stifel, and Oppenheimer all downgraded Insulet stock within the last 36 hours, citing challenges in market retention and competition. Truist and Oppenheimer highlighted concerns over churn and growth in the type 2 diabetes segment, while Stifel reduced its price target due to pump market dynamics. Insulet’s own earnings call revealed a revised 2026 revenue growth forecast of 20%-22% amid adjustments to U.S. assumptions. The company also cut its full-year sales guidance from $3.277B to $3.331B to $3.250B to $3.304B. These developments contributed to a sharp drop in investor sentiment.

What The Data Shows

The stock has fallen 19.2% over the last eight sessions, from $165.00 to $133.26, and currently trades within its 52-week range of $138.79 to $354.88. Insulet’s market cap is $11.8B, with a P/E of 38.9 and a beta of 1.09. Recent insider transactions show mixed activity, with three directors buying shares on June 3 and one selling. Congressional trades include three buys and four sells by Donald J. Trump in the last 90 days. The stock’s intraday volume was unusually high, though no unusual options activity was reported.

What To Watch

The company’s guidance cut and analyst downgrades suggest continued scrutiny ahead. Investors should monitor the 2027 outlook for clarity on type 2 diabetes retention and market share dynamics. Coverage breadth remains elevated, with 20 stories from 12 sources in the last 36 hours.